Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02650206 · ClinicalTrials.gov registry record · Phase 1
Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT02650206: Completed Phase 1 study, sponsored by Stanford University.
NCT02650206 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 56 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02650206, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The objective of this study is to test the hypothesis that liraglutide (commonly known as Victoza) can promote an anti-inflammatory macrophage phenotype in human adipose tissue and blood, thereby reducing localized and systemic inflammation which are risk factors for cardiovascular disease and may contribute to hyperglycemia. This will be done after 4 weeks of treatment during which weight will remain stable, and again after 12 weeks, during which liraglutide-related weight loss occurs.
Interventions
- DRUG Victoza (liraglutide) with dietician monitoring
- OTHER Placebo with dietician monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2015-01 |
| Est. Completion | 2019-09-27 |
| Phase | Phase 1 |
What the finished NCT02650206 record still lists
NCT02650206 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Victoza (liraglutide) with dietician monitoring is the first listed.
NCT02650206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02650206 about?
NCT02650206 is a clinical study titled "Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood". The objective of this study is to test the hypothesis that liraglutide (commonly known as Victoza) can promote an anti-inflammatory macrophage phenotype in human adipose tissue and blood, thereby reducing localized and systemic inflammation which are risk factors for cardiovascular disease and may c...
What is the current status of trial NCT02650206?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2015-01. Estimated completion is 2019-09-27.
What interventions are being tested in trial NCT02650206?
The interventions under investigation include: Victoza (liraglutide) with dietician monitoring (DRUG), Placebo with dietician monitoring (OTHER).
Who is sponsoring clinical trial NCT02650206?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02650206's enrollment target sits among peer trials
56 902nd of 2000 higher than 1,083 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia